🇺🇸 MEGF0444A in United States

9 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 9

Most-reported reactions

1. Atrial Fibrillation — 2 reports (22.22%)
2. Diabetic Foot — 1 report (11.11%)
3. Gastric Ulcer Haemorrhage — 1 report (11.11%)
4. Herpes Zoster — 1 report (11.11%)
5. Intestinal Obstruction — 1 report (11.11%)
6. Non-Cardiac Chest Pain — 1 report (11.11%)
7. Pancreatitis — 1 report (11.11%)
8. Polyneuropathy — 1 report (11.11%)

Source database →

Frequently asked questions

Is MEGF0444A approved in United States?

MEGF0444A does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for MEGF0444A in United States?

Genentech, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.